APA (7th ed.) Citation

Minckwitz, G. v., Rezai, M., Tesch, H., Huober, J., Gerber, B., Zahm, D. M., . . . Burchardi, N. D. (2016). Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer: The phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). European journal of cancer, 64, . https://doi.org/10.1016/j.ejca.2016.05.015

Chicago Style (17th ed.) Citation

Minckwitz, Gunter von, et al. "Zoledronate for Patients with Invasive Residual Disease After Anthracyclines-taxane-based Chemotherapy for Early Breast Cancer: The Phase III NeoAdjuvant Trial Add-oN (NaTaN) Study (GBG 36/ABCSG 29)." European Journal of Cancer 64 (2016). https://doi.org/10.1016/j.ejca.2016.05.015.

MLA (9th ed.) Citation

Minckwitz, Gunter von, et al. "Zoledronate for Patients with Invasive Residual Disease After Anthracyclines-taxane-based Chemotherapy for Early Breast Cancer: The Phase III NeoAdjuvant Trial Add-oN (NaTaN) Study (GBG 36/ABCSG 29)." European Journal of Cancer, vol. 64, 2016, https://doi.org/10.1016/j.ejca.2016.05.015.